Cite
HARVARD Citation
De Montalembert, M. et al. (n.d.). 13‐valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6‐17 years of age with sickle cell disease previously vaccinated with 23‐valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study. Pediatric blood & cancer. 62 (8), pp. 1427-1436. [Online].